Traitement dune endocardite mitrale SARM par la daptomycine

[1]  D. Levine,et al.  Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. , 2007, The American journal of medicine.

[2]  D. Bamberger.  Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin , 2007, Therapeutics and clinical risk management.

[3]  A. Wong-Beringer,et al.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. , 2006, Archives of internal medicine.

[4]  Vance G Fowler,et al.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.

[5]  J. Patel,et al.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  G. Eliopoulos,et al.  Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin , 2006, Antimicrobial Agents and Chemotherapy.

[7]  L. Cui,et al.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[8]  Brian T. Tsuji,et al.  Short-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations , 2005, Antimicrobial Agents and Chemotherapy.

[9]  M. Rybak,et al.  Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model , 2004, Antimicrobial Agents and Chemotherapy.

[10]  Jerome J. Schentag,et al.  Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.